Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Deferred Taxes: 2010-2025

Historic Deferred Taxes for Anika Therapeutics (ANIK) over the last 13 years, with Sep 2025 value amounting to $3,000.

  • Anika Therapeutics' Deferred Taxes rose 101.63% to $3,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $252,000, marking a year-over-year increase of 113.87%. This contributed to the annual value of $260,000 for FY2024, which is 104.11% up from last year.
  • As of Q3 2025, Anika Therapeutics' Deferred Taxes stood at $3,000, which was up 200.00% from -$3,000 recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Deferred Taxes ranged from a high of $2.4 million in Q2 2021 and a low of -$2.8 million during Q4 2021.
  • In the last 3 years, Anika Therapeutics' Deferred Taxes had a median value of -$3,000 in 2025 and averaged -$549,909.
  • Examining YoY changes over the last 5 years, Anika Therapeutics' Deferred Taxes showed a top increase of 261.84% in 2021 and a maximum decrease of 1,055.19% in 2021.
  • Anika Therapeutics' Deferred Taxes (Quarterly) stood at -$2.8 million in 2021, then skyrocketed by 36.10% to -$1.8 million in 2022, then declined by 3.60% to -$1.8 million in 2023, then surged by 112.70% to $234,000 in 2024, then spiked by 101.63% to $3,000 in 2025.
  • Its Deferred Taxes was $3,000 in Q3 2025, compared to -$3,000 in Q2 2025 and $18,000 in Q1 2025.